Skip to content
10-Q

Quarterly Report

ESTRELLA IMMUNOPHARMA, INC. ESLA ESLAW

0001213900-26-058063

← back to feed
Filed
May 18, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 43.03M sh
Shares Diluted Q1 2026 · Mar 31, 2026 42.12M sh
Shares Diluted Q1 2026 · Mar 31, 2025 36.19M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$6.7M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$465.98K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$5.27M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$10.37M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$1.83M
Stockholders Equity Q1 2026 · Dec 31, 2024 $143.73K
Current Liabilities Q1 2026 · Mar 31, 2026 $8.93M
Current Liabilities Q1 2026 · Dec 31, 2025 $13.54M
Total Liabilities Q1 2026 · Mar 31, 2026 $8.93M
Total Liabilities Q1 2026 · Dec 31, 2025 $13.54M
Current Assets Q1 2026 · Mar 31, 2026 $2.16M
Current Assets Q1 2026 · Dec 31, 2025 $1.68M
Total Assets Q1 2026 · Mar 31, 2026 $3.66M
Total Assets Q1 2026 · Dec 31, 2025 $3.18M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.05
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.06
Eps Basic Q1 2026 · Mar 31, 2026 −$0.05
Eps Basic Q1 2026 · Mar 31, 2025 −$0.06
Sga Expense Q1 2026 · Mar 31, 2026 $891.79K
Sga Expense Q1 2026 · Mar 31, 2025 $694.11K
Rd Expense Q1 2026 · Mar 31, 2026 $1.4M
Rd Expense Q1 2026 · Mar 31, 2025 $1.41M
Net Income Q1 2026 · Mar 31, 2026 −$2.29M
Net Income Q1 2026 · Mar 31, 2025 −$2.1M
Operating Income Q1 2026 · Mar 31, 2026 −$2.29M
Operating Income Q1 2026 · Mar 31, 2025 −$2.1M
Stock Repurchased Q1 2026 · Jan 30, 2024 $1M